Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a rare, chronic B-cell lymphoma with high heritability. We conduct a two-stage genome-wide association study of WM/LPL in 530 unrelated cases and 4362 controls of European ancestry and identify two high-risk loci associated with WM/LPL at 6p25.3 (rs116446171, near EXOC2 and IRF4; OR = 21.14, 95% CI: 14.40–31.03, \( P = 1.36 \times 10^{-54} \)) and 14q32.13 (rs117410836, near TCL1; OR = 4.90, 95% CI: 3.45–6.96, \( P = 8.75 \times 10^{-19} \)). Both risk alleles are observed at a low frequency among controls (~2–3%) and occur in excess in affected cases within families. In silico data suggest that rs116446171 may have functional importance, and in functional studies, we demonstrate increased reporter transcription and proliferation in cells transduced with the 6p25.3 risk allele. Although further studies are needed to fully elucidate underlying biological mechanisms, together these loci explain 4% of the familial risk and provide insights into genetic susceptibility to this malignancy.

DOI: 10.1038/s41467-018-06541-2

Correspondence and requests for materials should be addressed to M.L.M. (email: Mary.McMaster@nih.hhs.gov). A full list of authors and their affiliations appears at the end of the paper.
Waldenström macroglobulinemia (WM) is a subset of lymphoplasmacytic lymphoma (LPL) characterized by the presence of an immunoglobulin type M (IgM) monoclonal gammopathy1. Together, WM/LPL account for 2% of all non-Hodgkin lymphoma, with an estimated 2330 new cases diagnosed per year in the US2. Family history of WM/LPL or related lymphoproliferative disorder is strongly associated with WM/LPL risk3,4. Autoimmunity and select infections are also associated with WM/LPL risk3,5,6, and limited data suggest a possible relationship with certain lifestyle and occupational factors7, but overall little is known about its etiology. A somatic driver mutation, MYD88 p.L265P, occurs in most cases of WM8. However, germline MYD88 (myeloid differentiation primary response 88) mutations have not been observed, and despite early promising findings by linkage analysis9, no predisposing gene mutations have been conclusively reported to date. Characterizing the genetic factors influencing susceptibility to WM/LPL is an important step toward understanding its etiology. To discover genetic loci for WM/LPL susceptibility, we perform a two-stage genome-wide association study (GWAS) of WM/LPL, leveraging a family-based oversampling approach in the discovery followed by replication in an independent, predominantly non-familial, cohort. Here we report new susceptibility loci at 6p25.3 and 14q32.13 for WM/LPL and provide insights into the genetic etiology of this distinctive B-cell lymphoma.

Results

Discovery population, genotyping, and analysis. Oversampling cases with a family history of hematologic malignancy, we genotyped 244 WM/LPL cases of European descent (Supplementary Table 1), including 98 unrelated cases (40%) from high-risk families, using the Illumina OmniExpress SNP microarray chip and selected controls previously genotyped on the OmniExpress or Omni2.5,11,12. Following application of rigorous quality-control metrics, data for 603,492 SNPs with minor allele frequency (MAF) >1% in 217 unrelated cases and 3798 controls of European ancestry remained for analysis (Methods, Supplementary Table 2). A quantile–quantile plot of the association results with genotyped SNPs, adjusted for age, sex, and principal components, revealed enrichment of small P-values based on a log-additive genetic model and a small degree of over-dispersion (λ = 1.05), consistent with other GWAS and due in part to possible polygenic effects13 (Supplementary Fig. 1a). Several SNPs at chromosome 6p25.3 reached genome-wide significance with P-values between 1.22 × 10⁻⁸ and 5.64 × 10⁻²⁰ (Supplementary Fig. 2a).

To refine the association signal and identify other regions potentially associated with risk, we imputed common SNPs using the Haplotype Reference Consortium panel14. Following imputation, the strongest association at 6p25.3 was rs116446171 (P = 1.39 × 10⁻⁴⁸; information score = 0.9985; Supplementary Fig. 2b), a well-imputed SNP between EXOC2 (Exocyst complex component 2, also known as Sc5) and IRF4 (Interferon regulatory factor 4). A second SNP, rs76106586, was highly significant and in strong linkage disequilibrium (LD; r² = 1.0) with rs116446171. Although other SNPs appeared to be strongly associated with risk, conditional association analyses suggest a single signal accounted for the association in this region (Supplementary Table 3). SNPs at chromosome 14q32.13 also reached genome-wide significance, and conditional analyses suggest there may be more than one independent signal at 14q32.13 (Supplementary Fig. 2b; Supplementary Tables 4, 5).

Independent replication without familial enrichment. Eleven SNPs (Supplementary Table 6) with P ≤ 5 × 10⁻⁶ in the discovery analyses were selected for de novo replication in an additional 313 WM/LPL cases, with 24 (8%) reporting a positive family history, and 564 controls of European ancestry (Supplementary Tables 1, 2). The combined analysis of 530 WM/LPL cases and 4326 controls confirmed two distinct loci at chromosome 6p25.3 (rs116446171; odds ratio (OR) = 21.14, 95% confidence interval (CI) = 14.40–31.03, P = 1.36 × 10⁻⁵⁰) and 14q32.13 (rs117410836, OR = 4.90, 95% CI = 3.45–6.96, P = 8.75 × 10⁻¹⁰), as shown in Table 1 and Fig. 1. Both SNPs were well-imputed in the discovery (information scores >0.96), and technical validation using Taqman or Sanger sequencing showed >99% concordance between imputed and genotyped calls for both SNPs (Supplementary Table 7). The SNPs were genotyped using two different genotyping platforms in the replication, suggesting that our results are not due to platform artifact. Although the effect estimates were attenuated in the replication, suggesting some inflation due to winner’s curse and/or oversampling of familial cases in the discovery, both SNPs replicated with highly statistically significant P-values (P = 2.54 × 10⁻¹³ and 1.16 × 10⁻⁵ for rs116446171 and rs117410836, respectively, Table 1). The effects were similar when the analysis was limited to WM cases (rs116446171: OR = 24.41, 95% CI = 16.46–36.23, P = 7.43 × 10⁻⁵⁷, rs117410836: OR = 5.14, 95% CI = 3.56–7.43, P = 2.78 × 10⁻¹⁸, Supplementary Table 6). A suggestive second independent signal was observed at 14q32.13 with a directly genotyped SNP (rs179159, r² = 0.002, P = 4.66 × 10⁻⁷; Supplementary Table 6), which was slightly attenuated after conditioning on rs117410836 (P = 3.16 × 10⁻⁶). No other locus replicated.

Risk-variant enrichment in WM/LPL families and heritability. To assess whether the risk variants occurred at a higher than expected frequency within high-risk families, we genotyped the two loci in available affected relatives of familial cases. In families in which the index case had the rs116446171 risk variant, 76% of first-degree relatives with WM or its precursor, IgM monoclonal gammopathy of undetermined significance (MGUS), also carried the risk variant (Supplementary Table 8). Similarly, in families in which the index case had the rs117410836 risk variant, 86% of first-degree relatives with WM or IgM MGUS also carried the risk variant. In both instances, the risk variant frequency in affected relatives exceeded the expected 50% distribution (Pbinomial = 0.01 for rs116446171 and Pbinomial = 0.03 for rs117410836), which is consistent with theoretical models of familial co-segregation15.

Exploration of heritability in a broader sense, using effect estimated from the replication, indicated that these two loci explain 4% of the familial risk for WM/LPL. When we explored the potential contribution of all common variants to the heritability, we estimated that common SNPs could explain ~25% (95% CI = 15.4–34.5%) of the heritability as a whole, suggesting more common loci are likely to be discovered with larger sample sizes.

Functional annotation of rs116446171. rs116446171 is located 679 base pairs (bp) downstream of the 3’ untranslated region (UTR) of EXOC2, in a region bounded proximally by IRF4 and DUSP22 (Dual specificity phosphatase 22) and distally by EXOC2 (Fig. 2a). To determine whether rs116446171 might be a functional susceptibility variant, we performed in silico analyses that indicated the SNP is located in a region overlapping enhancer histone marks, histone H3 lysine 4 mono-methylation (H3K4me1) and lysine 27 acetylation (H3K27ac), in B-lymphoblastoid cell lines (Supplementary Fig. 3). Analysis of promoter capture Hi-C data16 showed that this region interacts with the IRF4 and, to a lesser extent, DUSP22 promoters in naive and total primary B-cells (Supplementary Fig. 3), consistent with reports of long-range enhancer-promoter interactions17,18.
silico analyses indicated that the rs116446171 (C) allele (“wild type”) is a predicted binding site for microRNA (miR) miR-378a-5p, and the single-nucleotide change from wild type (C) to risk (G) variant converts the nucleotide sequence to a binding site for a different miR, miR-324-3p (Fig. 2b).

No evidence for significant cis-eQTLs (expression quantitative trait loci) within Epstein-Barr virus (EBV)-transformed lymphocytes or whole blood was observed from analysis of Genotype-Tissue Expression Project (GTEx) data (Supplementary Table 9). rs116446171 is not located within the 3’UTR of the annotated transcript of EXOC2; however, alternative cleavage and polyadenylation has known capability to alter the length of 3’UTR regions19. Cell-type-specific polyadenylation occurs in the immunoglobulin locus and mature B-cells, resulting in transcript isoforms that lead to changes in protein structure20. Therefore, we explored in silico data for evidence for an extended UTR for EXOC2 (Supplementary Fig. 4). Based on published 3’ end-sequencing data performed by various groups20–22, we found evidence that rs116446171 could be

---

**Fig. 1** Regional association plots of two SNPs associated with the risk of WM/LPL. a Chromosome 6p25.3 (rs116446171) and b chromosome 14q32.13 (rs117410836). Shown are the −log_{10} association P-values from the discovery log-additive genetic model for all SNPs in the region (dots) and combined discovery and replication fixed-effects analysis (diamonds). The lead SNPs are shown in purple, with results from both the discovery (small diamonds) and combined (large diamonds) analyses. Estimated recombination rates (from 1000 Genomes) are plotted in blue. The SNPs surrounding the most significant SNP are color-coded to reflect their correlation with this SNP. Pairwise r^2 values are from 1000 Genomes European data. Locations of recombination hotspots are depicted by peaks corresponding to the rate of recombination. Genes, position of exons and direction of exons and direction of transcription from UCSC genome browser (http://genome.ucsc.edu) are denoted. Plots were generated using LocusZoom (http://csg.sph.umich.edu/locuszoom).
an enhancer in normal and malignant B-cells as well as other cell types. We then determined whether the SNP can cause changes to the secondary structure of the RNA of EXOC2, using RNAfold Webserver to predict in silico the centroid model with minimum free energy structures and base pair probabilities in the region surrounding rs116446171. As shown in Supplementary Fig. 5, the risk variant is predicted to induce a bulge in the region compared to the other variant. Data from cBioPortal and COSMIC for the closest gene, EXOC2, indicated a low frequency of somatic mutations in hematopoietic and lymphoid tissues, suggesting that occurrence of age-dependent clonal somatic mosaicism is unlikely to account for our results.

In vitro functional evaluation of rs116446171. To further explore the functional role of the rs116446171 risk variant, we used an enhanced green fluorescent protein (EGFP) reporter assay to estimate transcript levels. In addition to the pCS-EGFP-3′G (risk) construct, we also created pCS-EGFP-3′C (wild type, WT) and pCS-EGFP-3′Δ (null) constructs to use as comparators. Stably transduced HEK293T cell lines were grown for conducting the assays. Cells transduced with the risk allele reporter pCS-EGFP-3′G showed significantly increased EGFP fluorescence compared to the WT, Null, and the commercial EGFP reporters (Fig. 3a). Quantitative PCR analysis showed significantly higher EGFP mRNA levels in cells harboring the risk variant (Fig. 3b), possibly resulting from increased transcription or translational controls such as stability of EGFP mRNA. Furthermore, cells harboring the Null construct had significantly decreased EGFP mRNA levels, suggesting the deleted segment of DNA harboring the SNP might have an important role in the self-maintenance of

Table 1 Association statistics for two independent SNP genotypes and WM/LPL risk

| Nearest gene | SNP            | Positiona | Variant Eff/Oth | Stage | EAF controls | Cases/controls n/n | OR (95% CI)       | P-value |
|--------------|----------------|-----------|----------------|-------|--------------|--------------------|--------------------|---------|
| 6p25.3       | EXOC2 rs116446171 | 484453    | G/C            | Stage 1 | 0.0191 | 217/3798 | 56.44 (32.89, 96.85) | 1.59E−48 |
|              |                |           |                | Stage 2 | 0.0195 | 312/564 | 7.71 (4.46, 13.33)   | 2.54E−13 |
|              |                |           |                | Combined | 0.0195 | 529/4362 | 21.14 (14.40, 31.03) | 1.36E−54 |
| 14q32.13     | Intergenic rs117410836 | 96051974 | C/T            | Stage 1 | 0.0266 | 217/3798 | 10.62 (6.17, 18.29)  | 1.63E−17 |
|              |                |           |                | Stage 2 | 0.0355 | 306/563 | 2.81 (1.77, 4.45)    | 1.16E−05 |
|              |                |           |                | Combined | 0.0355 | 523/4361 | 4.90 (3.45, 6.96)    | 8.75E−19 |

For stages 1 and 2, P-values were generated using logistic regression. For the combined stage, the odds ratio and P-values were generated using a fixed-effects model controlling for age, gender and genotyping center.

WM Waldenström macroglobulinemia, LPL lymphoplasmacytic lymphoma, SNP single-nucleotide polymorphism, Eff effect, Oth other, EAF effect allele frequency, n number, OR odds ratio, CI confidence interval

aGenome coordinates are from NCBI human genome GRCh37/human genome (hg) build 19

bVariant associated with an effect on risk of WM/LPL

Fig. 2 Genomic position and alignments of rs116446171 to miRs. a Schematic representation of the position of rs116446171 relative to the 3′ UTR of EXOC2 on chromosome 6 and b alignments of rs116446171 wild type and risk variants with the binding sites of microRNAs, miR-378a-5p and miR-324-3p.
transcriptional control of EGFP mRNA. We saw no effect on EXOC2 transcript levels (Supplementary Fig. 6). Transduced cells harboring the risk variant showed significantly increased cell proliferation, based on the MTT assay (Methods), compared to cells transduced with the empty, wild type, or null vectors (Fig. 3c).

To evaluate the functional effect of the miR-binding site conversion conferred by the risk variant, we created premiRNA expression plasmids and transfected cells containing the wild type (C) or risk (G) variant (Methods). Overexpression of either premiR-378a-5p and premiR-324-3p in cells harboring the wild type or the risk variant decreased EGFP protein fluorescence (Fig. 4). However, no miR-specific effects were observed in the transfected cells overexpressing premiR-378a-5p or miR-324-3p, respectively (Supplementary Fig. 7), suggesting that the observed phenotypes in the cells harboring the risk variant might not be due to direct interference of the miRs with translation.

To further investigate the possible role of the miR-324-3p binding site created by the risk variant, we cloned 2, 4, or 8 tandem repeats of the 25-bp pair (bp) sequence centered around rs116446171G/C into the 3′UTR of the EGFP reporter, in both cis and trans orientations (Methods). We observed a proportional increase in EGFP mRNA transcript levels (Fig. 5a) and a similar effect on cellular proliferation (Fig. 5b) from the constructs incorporating increasing numbers of repeats of the rs116446171 risk variant that appeared to be dose-dependent in cis but, as expected, not in trans. These data suggest rs116446171 alters a binding site for miRNA. The miR-324-3p binding site results in increased gene expression. Previous studies have shown that miRs can influence tumorigenesis through various processes, and miR-324-3p induces promoter-mediated expression of RelA, a subunit of NF-κB, and the NF-κB signaling network is important in the pathogenesis of B-cell malignancies, including WM.

However, the precise mechanism by which non-canonical miR binding might increase WM/LPL risk is unclear.

Functional annotation of rs117410836. The most significant SNP marker at 14q32.13 (rs117410836) is located near an uncharacterized long non-coding RNA (IncRNA; LINC02318), GLRX5 (glutaredoxin 5), and members of the T-cell leukemia (TCL) gene family (TCL1A, TCLIB, and TCL6). rs117410836 resides in a repressive chromatin domain with histone H3 lysine 27 trimethylation (H3K27me3) (Supplementary Fig. 3). In silico analyses using Hi-C data suggest that the region containing a linked SNP (rs115066963; \( r^2 = 0.75 \)) interacts with the TCL1A promoter in total primary B-cells (Supplementary Fig. 3; Methods).

Discussion

In this study, we used a two-stage genome-wide approach to identify association between genetic variants and the risk of WM/LPL. We oversampled familial WM/LPL cases to enrich for potential susceptibility loci in our discovery stage and used an independent, predominantly non-familial sample to replicate our results. We found two loci at 6p25.3 and 14q32.13 associated with WM/LPL risk in individuals of European ancestry.

Definitive identification of the functional variants and genes remains a major challenge of GWAS. In this study, the most significant SNP, rs116446171 (6p25.3), is identical to that shown to be highly associated with diffuse large B-cell lymphoma in European and East Asian populations. While this observation is congruent with data supporting the co-aggregation of B-cell disorders, we cannot yet exclude the possibility that another highly significant linked SNP, such as rs76106586, is responsible for the observed association.

rs116446171 is located in proximity to EXOC2, IRF4, and DUSP22. These genes and their associated transcriptional programs have been implicated in a variety of lymphoid cancers and are plausible WM/LPL susceptibility genes. IRF4 expression is aberrantly downregulated in WM/LPL, specifically in the plasma cell compartment. IRF4 has a critical role in plasma cell differentiation, class-switch recombination, and germinal center fate decisions, and negatively regulates Toll-like receptor (TLR) signaling by binding MYD88. DUSP22 modulates immune and inflammatory responses through regulation of MAPK (mitogen-activated protein kinase) signaling and suppresses IL6/STAT3 (interleukin 6/signal transducer and activator of transcription)-mediated signaling, an important MYD88-independent mechanism for WM cell growth and survival. EXOC2 interacts with Ral (RAS-like proto-oncogene) proteins at the nexus of viral exposure and host immune response and other cellular functions has been implicated in cancer as well as in the development and function of the innate immune system. Specific IncRNAs influence gene expression programs, including the NF-κB signaling pathway, interact with transcription factors, and have been shown to be induced via the canonical TLR pathway involving MYD88 and NF-κB proteins.

A large effect size observed for rs116446171 in 6p25.3 near cases that are more likely to harbor disease variants, but remained pronounced in our discovery, where we oversampled familial cases and are plausible WM/LPL susceptibility genes. IRF4 expression is aberrantly downregulated in WM/LPL, specifically in the plasma cell compartment. IRF4 has a critical role in plasma cell differentiation, class-switch recombination, and germinal center fate decisions, and negatively regulates Toll-like receptor (TLR) signaling by binding MYD88. DUSP22 modulates immune and inflammatory responses through regulation of MAPK (mitogen-activated protein kinase) signaling and suppresses IL6/STAT3 (interleukin 6/signal transducer and activator of transcription)-mediated signaling, an important MYD88-independent mechanism for WM cell growth and survival.

The susceptibility locus at 14q32.13, rs117410836, maps most closely to the previously uncharacterized IncRNA, LINC02318. IncRNA regulation of transcription, cytokine production and other cellular functions has been implicated in cancer as well as in the development and function of the innate immune system. Specific IncRNAs influence gene expression programs, including the NF-κB signaling pathway, interact with transcription factors, and have been shown to be induced via the canonical TLR pathway involving MYD88 and NF-κB proteins.

A large effect size observed for rs116446171 in 6p25.3 near cases that are more likely to harbor disease variants, but remained pronounced in our discovery, where we oversampled familial cases and are plausible WM/LPL susceptibility genes. IRF4 expression is aberrantly downregulated in WM/LPL, specifically in the plasma cell compartment. IRF4 has a critical role in plasma cell differentiation, class-switch recombination, and germinal center fate decisions, and negatively regulates Toll-like receptor (TLR) signaling by binding MYD88. DUSP22 modulates immune and inflammatory responses through regulation of MAPK (mitogen-activated protein kinase) signaling and suppresses IL6/STAT3 (interleukin 6/signal transducer and activator of transcription)-mediated signaling, an important MYD88-independent mechanism for WM cell growth and survival.

The susceptibility locus at 14q32.13, rs117410836, maps most closely to the previously uncharacterized IncRNA, LINC02318. IncRNA regulation of transcription, cytokine production and other cellular functions has been implicated in cancer as well as in the development and function of the innate immune system. Specific IncRNAs influence gene expression programs, including the NF-κB signaling pathway, interact with transcription factors, and have been shown to be induced via the canonical TLR pathway involving MYD88 and NF-κB proteins.

In conclusion, we performed a GWAS of WM/LPL and identified two independent loci that are associated with the risk of WM/LPL with substantially higher than expected estimated odds ratios for a GWAS of an adult cancer. It is remarkable that the effect size for 6p25.3 is substantially different for WM/LPL compared to other subtypes of NHL. The effect size was especially pronounced in our discovery, where we oversampled familial cases that are more likely to harbor disease variants, but remained highly significant in a predominantly non-familial replication set. The large effect size observed for rs116446171 in 6p25.3 near IRF4, DUSP22, and EXOC2 and preliminary in silico and functional evidence suggest we may have discovered an important non-coding variant for WM risk. Familial co-segregation analyses are necessary to understand the implications for familial risk and any warranted clinical application. Additional functional and epidemiological studies are needed to clarify underlying biological mechanisms and to identify additional susceptibility loci that may influence disease risk.

Methods

Study approval. Each participating study obtained written informed consent from all participants and approval from its respective human subjects review committee, as follows: CPS-II: Emory University Institutional Review Board; ENGELA: IRB0000888—Comité d’Evaluation Éthique de l’Inserm IRB #1; EPIC: Imperial College London; Epilymph: International Agency for Research on Cancer; HPFS: Harvard TH Chan School of Public Health Institutional Review Board; Iowa-Mayo SPORE: University of Iowa and Mayo Clinic Institutional Review Board; Mayo CC: Mayo Clinic Institutional Review Board; MSKCC: Memorial Sloan-Kettering
**Phenotype definition.** LPL was defined according to World Health Organization (WHO)\(^ {1,57} \) criteria. WM was defined according to WHO\(^ {1,57} \) and required the presence of both an LPL infiltrate in the bone marrow together with a monoclonal immunoglobulin type M (IgM) protein in the serum. In cases where histopathologic criteria for LPL were met but serum protein electrophoresis data were not available, the case was classified as LPL. Diagnoses were validated for all cases by medical and pathology reports. All cases were unrelated. Family history of WM/LPL or other B-cell malignancy (i.e., chronic lymphocytic leukemia (CLL), other non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, or multiple myeloma) was ascertained by self-report, and positive family history was validated in a subset (83%).

**Discovery population.** Cases for the stage 1 discovery analysis included 207 participants in a WM family study at the National Cancer Institute (NCI Family)\(^ {7} \) and 37 cases identified through a case–control study of NHL and CLL at the Mayo Clinic (Mayo CC). The 244 stage 1 cases included 98 reporting a family history of WM/LPL (n = 42) or other B-cell malignancy (n = 56), 118 cases reporting no family history, and 28 cases with unknown family history. Stage 1 controls (n = 3812) were obtained from a previous GWAS of NHL\(^ {11} \) and included 987 lymphoma-free controls from four US-based studies (National Cancer Institute—Surveillance, Epidemiology, and End Results Interdisciplinary Case-Control Study of Non-Hodgkin lymphoma (NCI-SEER); the Women’s Health Initiative (WHI); a population-based case–control study in Connecticut women (Yale); and Mayo CC) and 2825 cancer-free controls from a study of prostate cancer in the Prostate, Lung, Colon, and Ovarian (PLCO) Cancer Screening Trial\(^ {12} \) (Supplementary Table 1). Characteristics of the discovery population are shown in Supplementary Table 2.

**Discovery genotyping and quality control.** All WM/LPL cases with sufficient DNA (n = 244) were genotyped on the Illumina OmniExpress SNP microarray chip at the NCI Cancer Genomics Research Laboratory (CGR). Genotypes were called using Illumina GenomeStudio software, and rigorous quality control metrics were employed to ensure that the resulting data were of high quality (Supplementary Table 10). All data analyses and management were conducted.
Imputation of variants. To allow us to evaluate the genome more comprehensively for SNPs associated with WM, we imputed SNPs in the stage 1 discovery GWAS using the Michigan Imputation Server (https://www.sanger.ac.uk/resources/software/shapeit2/snpinfo) and the HaploType Reference Consortium (HRCv1) panel (https://www.sanger.ac.uk/resources/software/shapeit2/haploType-reference-consortium) following co-phasing using SHAPEIT (https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html). For imputation, SNPs with MAF < 1% were not excluded. Association testing on the imputed data was conducted using the Frequentist association module in SNPTEST v.2.5.2 (https://mathgen.stats.ox.ac.uk/genetics_software/snpinfo/snpinfo.html), assuming dosages for the genotypes, a log-additive model, and adjusting for age, sex and two significant principal components. Tested SNPs with MAF filter < 2.5% for cases and < 1% for controls or with SNPTEST INFO score filter < 0.3 were excluded, resulting in 6,440,053 autosomal SNPs.

Replication population. An independent stage 2 replication population included 313 WM/LPL cases from the NCI Family study (n = 29), Mayo CC/Iowa-Mayo SPORE (n = 105), Memorial Sloan Kettering Lymphoproliferative Disorders Study (MSKCC) (n = 64), and ten additional studies (Supplementary Table 1). Among these 313 cases, 24 had a family history of a hematologic malignancy and 105 reported no family history; family history information was reported as unknown or was unavailable for the remainder. The stage 2 controls (n = 564) were obtained from Mayo CC/Iowa-Mayo SPORE (n = 167), MSKCC (n = 302), and stage 1 (n = 444).
and eight other studies4,12 (Supplementary Table 1). Characteristics of the replication population are shown in Supplementary Table 2.

**SNP selection for replication.** After ranking the SNPs by P-value and filtering for linkage disequilibrium (LD; r² < 0.05), we selected eleven SNPs from the most promising loci identified in stage 1 after imputation with P < 5 × 10⁻⁶ (Supplementary Table 6) for de novo replication in an independent sample of 313 WM/LPL unrelated cases and 564 controls. We chose the most significant imputed and genotyped SNPs at our two top loci (chromosome 6p25.3 and chromosome 1q42.13) and, whenever possible, the most significant SNP (genotyped or imputed) for additional promising loci with P < 1 × 10⁻⁶ in the discovery. Imputed SNPs with an information score ≤0.75 were excluded. Furthermore, only SNPs with MAF > 1% were selected for replication, and no SNPs proceeded to replication if they occurred in regions where they appeared as singleton or obvious artifacts. Of the 11 SNPs selected for replication, five were directly genotyped and the remaining six were imputed in the discovery.

**Replication genotyping and analysis.** We conducted genotyping on independent case–control sets in three centers using custom genotyping assays developed for either TaqMan (Applied Biosystems; validated at the NCI CGR) or Sequenom (Sequenom Laboratories; validated at the Mayo Clinic and MSKCC), or Sanger sequencing (for a single SNP, rs117410836, for which a custom TaqMan assay could not be designed). Genotyping was performed by the NCI CGR, the Mayo Clinic and MSKCC and included duplicates for quality control. Following exclusions for genotyping failures and self-reported non-European ancestry, data for 313 cases and 564 controls remained for analysis (Supplementary Table 10). Association testing assumed a log-additive model, adjusting for age, sex, Ashkenazi ancestry, and genotyping center, which appeared to be an appropriate model for the top SNPs (Supplementary Table 11). The results from the discovery and replication were then combined using a fixed-effects meta-analysis with inverse variance weighting based on the estimates and standard error from each stage.

**Technical validation.** Technical validation was conducted for all SNPs taken forward for replication on a subset of cases (n = 213) and controls (n = 478) from the discovery. Comparing genotype calls from TaqMan assays or Sanger sequencing with genotyped or imputed data from the GWAS showed high concordance (>99%) for all SNPs. Concordance for both genome-wide significant SNPs (rs116446171 and rs117410836) and the secondary signal at chromosome 14 (rs179159) was >99% (Supplementary Table 7).

**Assessment of enrichment among high-risk families.** Of the 122 WM/LPL cases in this study reporting a family history, 100 were enrolled in a family study of WM. Among these cases, 21 had the risk variant at rs116446171 or rs117410836 and at least one living relative diagnosed with a relevant B-cell disorder and DNA available for genotyping. To assess whether the risk variants occurred at a higher frequency than expected within high-risk families, we genotyped available affected relatives using the Illumina OmniExpress. After employing rigorous quality control metrics, genotyping data were available for 58 relatives, including 32 first-degree relatives and 14 more distantly related relatives with WM, IgM MGUS, or other lymphoproliferative disorders (Supplementary Table S8). For index cases, the risk variant at either locus, we computed the frequency with which their affected relatives carried the same effect variant and used the binomial test to determine whether the frequency was greater than expected under the assumption that 50% of first-degree relatives would share the same variant.

**Heritability analysis.** To estimate the familial risk explained by these loci for WM/LPL, we computed the contribution of each independent SNP to the heritability (8). To estimate the effect variant at either locus, we computed the frequency with which their affected relatives would share the same variant.

**Functional annotation of rs116446171.** To explore whether the rs116446171 SNP was encompassed within EXOC2 transcripts in any cell type, we analyzed published reference data from Poly(A)site (http://www.polyasite.unibas.ch/), an annotation tool built using a total of over 400 million reads from 78 3’ end sequencing libraries generated with the Trueseq RiboZero® pro and end-sequencing protocol9,36. Poly(A) sites are based on the protein-coding genes and long non-coding RNAs (lncRNAs) contained in the UCSC Basic Table of GENCODE V19. The original data and experimental methods are described by Lianoglou37. We analyzed data from the Genotype-Tissue Expression (GTEX) Project (https://www.gtexportal.org/home) from whole blood, brain, lymphocytes, and EBV-transformed lymphoblastoid cell lines to determine the presence of cis expression quantitative trait loci (eQTLs), adjusted for principal components. We explored possible effects of variation at rs116446171 on secondary RNA structure using RNAfold Server (http://mrna.bi.univie.ac.at/cgi-bin/rna-formulaire/note/site/RNAfold.cgi). The secondary structure of the transcript with an odd number of introns that predicts secondary minimum free energy structures and base pair probabilities from single RNA or DNA sequences45. In parallel, these SNPs were compared to a collection of internally processed genomic data sets. Model-based analysis of ChIP-seq (MACs) package46 was used to identify H3K4me1, H3K4me3, and H3K27ac peaks from GSE58093 ChIP-seq data47. Reference genome data was obtained from the Roadmap Epigenomics Project (http://www.roadmapepigenomics.org); other ChIP-seq and DNA-seq data were from the ENCODE project (https://www.encodeproject.org). Signal tracks (reads per million) were generated using a 200-base pair (bp) sliding window and a step size of 20 bp. To determine potential SNP–gene promoter interactions, we used Capture Hi-C (http://promoter.bx.psu.edu/hic/view.php), a method for profiling chromosomal interactions involving targeted regions of interest, such as gene promoters, globally and at high resolution. We used promoter Capture Hi-C data in 17 primary hematopoietic cell types48. Regions showing significant chromatin interactions with CHICAGO (http://regulatorygenomicsgroup.org/chicago) scores ≥5 were downloaded from https://osf.io/uit2p/.

**Selection of SNP for functional evaluation.** Our main finding, rs116446171, is located 679 bp downstream of the 3’ UTR of the EXOC2 gene. Although it is not predicted to be contained in any EXOC2 transcript, we chose to further evaluate this SNP for possible functional relevance based on (1) prior evidence that this rs116446171 is also the most significant SNP associated with diffuse large B-cell lymphoma13,15; (2) the unusually large observed effect size on WM/LPL risk; (3) in silico evidence suggesting an association with regulatory elements in primary B-cells and the lymphoblastoid cell line, GM12878; and (4) the observation that the risk variant might affect a predicted miRNA binding site.

**Cell culture and generation of stable cell lines.** HEK293T cells were used because of their reliable growth and transfection profile and suitability for gene expression studies. HEK293T cells were obtained from American Type Culture Collection (293T ATCC® CRL-3216®; ATCC, Manassas, VA), where they were authenticated by Short Tandem Repeat (STR) profiling. The cells were maintained under standard cell culture conditions at 37°C in 5% CO₂ in a humid environment. The culture medium, DMEM, was purchased from Mediatech Inc. (Manassas, VA) and supplemented with 10% FBS from Gemini Bio Products (West Sacramento, CA). Plasmocin Prophylactic (InvivoGen, San Diego, CA) was used in the culture medium to prevent mycoplasma contamination. Lentiviral vectors were designed by transfection of HEK293T packaging cells with a three plasmid system49. To generate stable cell lines, HEK293T cells were seeded into 6-well plates for 24 h before infection with 5 multiplicity of infection (MOI) of lentivirus in OptiMEM (Invitrogen; Thermofisher Scientific, Waltham, MA) in the presence of 8 μg/ml polybrene (Sigma-Aldrich, Inc., St. Louis, MO). After 24 h, fresh DMEM was replaced with fresh DMEM with 10% FBS for another 24 h before selection in medium containing 1 μg/ml of puromycin, until the control cells were no longer viable. All the stably transduced cell lines were subsequently maintained in medium supplemented with 0.5 μg/ml of puromycin during experimentation.

**Plasmids and site-specific mutagenesis.** The EXOC2 3’ UTR Lenti-reporter-GFP (green fluorescent protein) vector was purchased from Applied Biological Materials Inc. (Richmond, BC, Canada, Catalog # MT-97118). To construct the reporter plasmids with the extended EXOC2 3’ UTR containing the wild-type, variant and deleted sequence (Supplementary Fig. 10a), a wild-type 987 bp fragment PCR-amplified with high Fidelity Platinum PCR SuperMix (Invitrogen) (forward 5’-GG CTTGTCAGGCGTTTACAAAG-3’; reverse 5’-CATGCAAAGATGACAAGAGC GCGTGTTTTTCTG-3’), was cloned into pCMV-GFP (Invitrogen). This plasmid was further cloned into the PuroGLO®-GFP vector with the Oxyrase® Plasmid Purification Kit (Sigma-Aldrich, Inc., St. Louis, MO). After digestion and purification, the plasmid was amplified and replaced the corresponding wild type fragment with Choo-Choo cloning kit. For generation of the deletion construct pCS-EFGP-3 ΔE, PCR fragment (forward 5’-CTCTGTTAATCTCCTGTCTTAATGG-3’; reverse 5’-TCTGTTAATCTCCTGTCTTAATGG-3’) was amplified and replaced the corresponding wild type fragment with Choo-Choo cloning kit. To construct the empty vector, the commercial EXOC3 3’ UTR
Expression and normalization of pre-microRNAs. PremiR-378a-5p (Cat # mir-p227) and PremiR-324-3p (Cat # mir-p193) were expressed in self-inactivated (SIN) lentiviral, plV-mi vectors purchased from BIOSETTA (San Diego, CA). The control vector (plV13) was created by insertion of a 118-bp random sequence into the Xhol site of the plV-mi vector (re-ligation of mir-p227 after deletion of the Xhol fragment containing the insert of mir-378a); 4 copies of the tandem repeats in the orientation inserted into the XhoI site of the plV-mi vector, which served as a loxas plasmid (plV18). All vectors express a rPuro (red fluorescent puroucinyl-N-acetyl transferee) gene and the measurement of the red fluorescence in cell lines after transfection can be used for normalization. Cells were transiently with the above constructs using lipofectamine to determine the effects of the microRNAs on the EGF reporter. The EGF reporter fluorescence was measured and normalized against transfection efficiencies in the same cell lines with different microRNA plasmids and normalized against the genomic copy number of EGF from cell lines transfected with WT, Variant, Null, 3’UTR of EXOC2 and vectors.

Cell proliferation assay. Live cells were enumerated at wavelength 570 nm using the MTT assay of mitochondrial enzymatic activity (CellTiter 96 Non-Radioactive Cell Proliferation assay, Promega Corp., Madison, WI).

Real-time quantitative RT-PCR. Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Louisville, KY) with on-column DNase digestion. Reverse transcription was performed with Accupower CycleScript RT Premix (Bioneer, Alameda, CA). Real-time quantitative PCR reactions were performed using SYBR green PCR Master Mix with 3 sets of EGFP primer (forward 5′-GCCAGCTCTGATACCA-3′, reverse 5′-GAGGCTGAGTTCCTACGGT-3′) and EGF primer (forward 5′-GAATGACACCGAACACATTG-3′, reverse 5′-GA CTTGGGTGCTCAGGTAGTG-3′). Triplicate reactions for the genes of interest and 4 endogenous controls (ACTB, B2M, GAPDH, and GUSB) were performed separately on the same cDNA samples by using CFX Connect Real-Time System (Bio-Rad). Proprietary primer sets for ACTB, B2M, GAPDH, and GUSB were purchased from RealTimePrimers, LLC (https://www.realtimprimers.com/). The mean cycle threshold (Ct) was used for the ΔΔCt computations of the relative transcript abundance.

Normalization for transduction efficiencies of cell lines. Genomic DNAs were purified with Quick-DNA Universal Kit (Zymo Research). Real-time quantitative PCR was performed using SYBR green PCR Master Mix with 3 sets of EGF primer (Set I: forward 5′-CTTCCTAAGGCTGCGCCATG-3′, reverse 5′-ATGGTATCCGCGCTCTCGGT-3′; Set II: forward 5′-GCTAGAAGCGCAGACCTTTCA-3′, reverse 5′-CTTCCATGGTGCCGCTGAG-3′; Set III: forward 5′-GACGATCACCCAAATTG-3′, reverse 5′-GATCGTGGTCTGGATG-3′), while GAPDH was used for the reference gene (Set I: forward 5′-CCCTCAGTTGCACTTACATGGT-3′, reverse 5′-GAGGGGCTGCCACATGCTTCTG-3′; Set II: forward 5′-GTGAAGTGGCAGGACCGACG-3′, reverse 5′-TGAGGCTGCAATAGAGGGCT-3′). The ratio of copy number of the integrated reporter gene in cell lines was calculated against the reference gene GAPDH.

Direct measurement of EGF and purofluoro fluorescence. EGF and purofluoro fluorescence were measured directly with 6-well plates with or without Triton X-100 (1%) treatment using Synergy H1 Hybrid Reader (BioTek, Winooski, VT) Gen5 Microplate Reader and Imager Software (ex/em for GFP: 485/519 nm; for purofluoro: 553/593 nm). Fluorescence measurements were performed using the bottom optic, orbital avenue with 2 mm diameter and 20 flashes per well. All the cell lines were cultured in the phenol red free DMEM media (Mediatech, Cornings, NY) supplied with 10% FBS to lower the background. All measurements were background subtracted (HEK293T cells with no plasmid transfection) and normalized against the genomic copy number of the EGF genes.

In silico miR-binding site prediction. miRBase (http://www.mirbase.org/search.shtml) homologous search with the wild type rs11646171 sequence detected significant homology with the mature microRNA, miR-378a-5p. rs11646171 sequence with a single C to G change eliminates that homology, and instead creates a new homology with the mature microRNA, miR-324-3p.

Statistical analysis for functional experiments. All the experimental data from cell viability and proliferation assays, EGF reporter assay, and quantitative PCR analysis were performed by the unpaired t-test and fitted with an exponential growth equation of Prism 6 from Windows from GraphPad Software (San Diego CA). Data are shown as means ± the standard error of the mean (s.e.m.) of values obtained for n replicates as indicated in the figure legends.

Disclaimer. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Data availability. The genotyping dataset generated during this study has been deposited in the dbGap repository with the accession code phs001284.v1.p1. All other relevant data generated for this study are available upon request from the authors.

Received: 17 November 2017 Accepted: 4 September 2018 Published online: 10 October 2018

References

1. Swedlow, S. H. et al. in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues 4th edn (eds Swedlow, S. H. et al.) (International Agency for Research on Cancer, Lyon, 2008).
2. Teras, I. R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 66, 443–459 (2016).
3. Kristinsson, S. Y. et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden. Blood 112, 3052–3066 (2008).
4. Altiere, A., Bermejo, I. J. L. & Hemminki, K. Familial aggregation of lymphoplasmacytic lymphoma with non-Hodgkin lymphoma and other neoplasms. Leukemia 19, 2342–2343 (2005).
5. Kishol, J., Gridley, G., Engels, E. A., McMaster, M. L. & Landgren, O. Chronic immune stimulation and subsequent Waldenström macroglobulinemia. Arch. Intern. Med. 168, 1903–1909 (2008).
6. Kristinsson, S. Y. et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenström macroglobulinemia. J. Natl Cancer Inst. 102, 557–567 (2010).
7. Royer, R. H. et al. Differential characteristics of Waldenstrom macroglobulinemia according to patterns of familial aggregation. Blood 115, 4464–4471 (2010).
8. Vajdic, C. M. et al. Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl Cancer Inst. Monogr. 2014, 87–97 (2014).
9. Treon, S. P. et al. MYD88 L265P somatic mutation in Waldenström macroglobulinemia. N. Engl. J. Med. 367, 826–833 (2012).
10. McMaster, M. L. et al. Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am. J. Hum. Genet. 79, 695–701 (2006).
11. Berndt, S. I. et al. Genome wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat. Genet. 45, 868–876 (2013).
12. Berndt, S. I. et al. Two susceptibility loci identified for prostate cancer aggressiveness. Nat. Commun. 6, 6889 (2015).
13. Yang, J. et al. Genomic inflation factors under polygenic inheritance. Eur. J. Hum. Genet. 19, 807–812 (2011).
14. McEvily, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nature Genet. 48, 1279–1283 (2016).
15. Hellbig, I., Hodge, S. E. & Ottman, R. Familial cosegregation of rare genetic variants with disease in complex disorders. Eur. J. Hum. Genet. 21, 444–450 (2013).
16. Javierre, B. M. et al. Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters. Cell 167, 1369–1384 (2016).
17. Mifsud, B. et al. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat. Genet. 47, 598–606 (2015).
18. Jin, F. et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature 503, 290–294 (2013).
19. Mayr, C. Regulation by 3′-untranslated regions. Ann. Rev. Genet. 51, 171–194 (2017).
20. Singh, I. et al. Widespread intronic polyadenylation diversifies immune cell transcriptomes. Nat. Commun. 9, 1716 (2018).
21. Lianoglou, S., Garg, V., Yang, J. L., Leslie, C. S. & Mayr, C. Ubiquitously
22. Gruber, A. J. et al. A comprehensive analysis of 3’ end sequencing data sets
23. Hofacker, I. L. Vienna RNA secondary structure server. Nucleic Acids Res. 31, 3429–3431 (2003).
24. Cerami, E. et al. The cBio cancer genomics portal: an open platform for
25. Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution.
48. Rapicavoli, N. A. et al. A mammalian pseudogene lncRNA at the interface of
expression.
51. Lemal, R. et al. TCL1 expression patterns in Waldenström macroglobulinemia. Mod. Pathol. 29, 83–88 (2016).
52. Zhou, W. et al. Mosaic loss of chromosome Y is associated with common
expression patterns of the same cell counterparts from chronic lymphocytic
lymphoma/Waldenström macroglobulinemia. Blood 99, 14182–14197 (2002).
53. Laine, J., Künstle, G., Obata, T., Sha, M. & Noguchi, M. The protooncogene
54. Kasahara, N. et al. TCL1 is an Akt kinase coactivator. Mol. Cell. 6, 395–407 (2000).
55. Pors, V. et al. The TCL1A oncoprotein interacts directly with the NF-κB
56. Zhou, W. et al. Mosaic loss of chromosome Y is associated with common
expression patterns of the same cell counterparts from chronic lymphocytic
lymphoma/Waldenström macroglobulinemia. Blood 99, 14182–14197 (2002).
57. Vui, K. et al. Population structure and control selection in genome-wide
association studies. PLoS ONE 3, e2551 (2008).
58. Pritchard, J. K., Stephens, M. & Donnelly, P. Inference of population structure
59. International HapMap Consortium et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449, 851–861 (2007).
60. Price, A. L. et al. Principal components analysis corrects for stratification in
genome-wide association studies. Nat. Genet. 38, 904–909 (2006).
61. Vijai, J. et al. Susceptibility loci associated with specific and shared subtypes of
lymphoid malignancies. PloS Genet. 9, e1003220 (2013).
62. Park, J. H. et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42, 570–575 (2010).
63. Pharoah, P. D. et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31, 33–36 (2002).
64. Yang, J. et al. Common SNPs explain a large proportion of the heritability for
human height. Nat. Genet. 42, 563–569 (2010).
65. Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating missing heritability for disease from genome-wide association studies. Am. J. Hum. Genet. 89, 294–305 (2011).
66. Zhang, Y. et al. Model-based analysis of ChiP-Seq (MACS). Genome Biol. 9, R137 (2008).
67. Kasowski, M. et al. Extensive variation in chromatin states across humans. Science 342, 750–752 (2013).
68. Falahati, R. et al. Chemoselection of allogeneic HSC after murine neonatal
transplantation without myeloablative or post-transplant immunosuppression. Mol. Ther. 20, 2180–2189 (2012).

Acknowledgements
We wish to thank Seth A. Brodie, PhD, for his critical reading of the manuscript and his intellectual contributions to the functional experimental approach. The Genotype-Tissue Expression (GTeX) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 03/07/2018. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN26120080001E. Further acknowledgements are provided in Supplemental Note 1.

Author contributions
M.L.M., S.B., J.Z., S.L.S., R.M., C.L., S.C., N.R., J.V., L.G., C.F.S., and N.E.C. participated in the working group
and/or supervised the genotyping. M.L.M., S.I.B., J.Z., S.L.S., S.A.L., C.M.V., K.E.S., G.K., E.E.B., A.Sm., L.R., H.H., N.P., A.L.F., A.J.N., B.B., Q.L., T.Z., K.E.N., L.F.T., W.C., L.R.T., H-O.A., P.M.B. J.M., A.Mo., B.K.L., R.C.H.V., S.M.A., A.Ma., W.R.D., M.Me., N.E.C. conducted epidemiologic studies and contributed samples to the GWAS and/or

naturecommunications.nature.com
Mary L. McMaster1, Sonja I. Berndt1, Jianqing Zhang6,2, Susan L. Slager3, Shengchao Alfred Li4, Claire M. Vajdic5, Karin E. Smedby6,7, Huihuang Yan3, Brenda M. Birmann8, Elizabeth E. Brown9, Alex Smith10, Geffen Kleistern3, Mervin M. Fansler11,12, Christine Mayr12, Bin Zhu4, Charles C. Chung4, Ju-Hyun Park13, Laurie Burdette4, Belynda D. Hicks4, Amy Hutchinson4, Lauren R. Teras14, Hans-Olov Adami15,16,17, Paige M. Bracci18, James McKay19, Alain Monnereau20,21,22, Brian K. Link23, Roel C.H. Vermeulen24,25, Stephen M. Ansell26, Ann Maria27, W. Ryan Diver28, Mads Melbye29,30, Akinyemi I. Ojesina2, Peter Kraft16,30, Paolo Bottferia31, Jacqueline Clavel20,21, Edward Giovannucci8,16,32, Caroline M. Besson33, Federico Canzian34, Ruth C. Travis35, Paolo Vineis36,37, Elisabete Weiderpass38,39,40, Rebecca Montalvan41, Zhaoming Wang42,43, Meredith Yeager4, Nikolaus Becker44, Yolanda Benavente45,46, Paul Brennan47,48, Lenka Foretova49, Marc Maynadie50, Alexandra Nieters51, Silvia de Sanjose45,46, Anthony Staines52,53, Lucia Conde54, Jacques Ribi55, Bengt Glimelius56, Henrik Hjalgrim57,58, Nisha Pradhan27, Andrew L. Feldman59, Anne J. Novak26, Charles Lawrence60, Bryan A. Bassis1, Qing Lan1, Tongzhang Zheng56, Kari E. North57,58, Lesley F. Tinker59, Wendy Cozen56,60,61, Richard K. Severson62, Jonathan N. Hofmann1, Yawei Zhang63, Rebecca D. Jackson64, Lindsay M. Morton1, Mark P. Purd65,66, Nilanjan Chatterjee166,67, Kenneth Offitt68, James R. Cerhan39, Stephen J. Chanock1, Nathaniel Rothman1, Joseph Vijai6,27, Lynn R. Goldin1, Christine F. Skibola68 & Neil E. Caporaso1

1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda 20892 MD, USA. 2Department of Epidemiology, School of Public Health and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham 35233 AL, USA. 3Department of Health Sciences Research, Mayo Clinic, Rochester 55905 MN, USA. 4Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick National Lab for Cancer Research, Frederick 20877 MD, USA. 5Centre for Big Data Research in Health, University of New South Wales, Sydney 2052 NSW, Australia. 6Department of Medicine, Solna Karolinska Institutet, Stockholm 17176, Sweden. 7Hematology Center, Karolinska University Hospital, Stockholm 17176, Sweden. 8Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston 02115 MA, USA. 9Department of Pathology, University of Alabama at Birmingham, Birmingham 35233 AL, USA. 10Department of Health Sciences, University of York, York YO10 5DD, UK. 11Tri-Institutional Training Program in Computational Biology and Medicine, Weill Cornell Graduate School, New York 10021 NY, USA. 12Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York 10065 NY, USA. 13Department of Statistics, Dongguk University, Seoul 100-715, Republic of Korea. 14Epidemiology Research Program, American Cancer Society, Atlanta 30333 GA, USA. 15Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden. 16Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston 02115 MA, USA. 17Institute of Health and Society, Clinical Effectiveness Research Group, University of Oslo, Oslo NO-0316, Norway. 18Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco 94118 CA, USA. 19International Agency for Research on Cancer (IARC), Lyon 69372, France. 20Epidemiology of Childhood and Adolescent Cancers Group, Inserm, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris F-94807, France. 21Université Paris Descartes, Paris 75006, France. 22Registry of Hematological Malignancies in Grinde, Institutt Bergoné, University of Bordeaux, Inserm, Team EPICENE, UMR 1219, Bordeaux 33000, France. 23Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City 52242 IA, USA. 24Institute for Risk Assessment Sciences, Utrecht University, Utrecht 3508 TD, The Netherlands. 25Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands. 26Department of Internal Medicine, Mayo Clinic, Rochester 55905 MN, USA. 27Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065 NY, USA. 28Division of Health Surveillance and Research, Department of Epidemiology Research, Statens Serum Institut, Copenhagen 2300, Denmark. 29Division of Medicine, Stanford University School of Medicine, Stanford 94305 CA, USA. 30Department of...
